About Verax Biomedical
Verax Biomedical is a company based in Marlborough (United States) founded in 1999. Verax Biomedical has raised $72.3 million across 12 funding rounds from investors including BioVentures MedTech Funds, Teknoinvest and KB Partners. The company has 23 employees as of December 31, 2022. Verax Biomedical offers products and services including Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test. Verax Biomedical operates in a competitive market with competitors including OpGen, Avails Medical, Resistell, NOWDiagnostics and HandyLab, among others.
- Headquarter Marlborough, United States
- Employees 23 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$498.01 K (USD)49as on Dec 31, 2023
-
Net Profit
-$10.76 K (USD)-207as on Dec 31, 2023
-
EBITDA
Not available
-
Total Equity Funding
$72.3 M (USD)
in 12 rounds
-
Latest Funding Round
$2.54 M (USD), Series D
Sep 18, 2019
-
Investors
BioVentures MedTech Funds
& 5 more
-
Employee Count
23
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Verax Biomedical
Verax Biomedical offers a comprehensive portfolio of products and services, including Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test.
Rapid test for detecting bacterial contamination in platelets
Enhanced test for Acinetobacter detection in platelets
Test for bacterial detection in red blood cells
Test for bacterial contamination in cell therapy products
People of Verax Biomedical
Unlock access to complete
Unlock access to complete
Funding Insights of Verax Biomedical
Verax Biomedical has successfully raised a total of $72.3M across 12 strategic funding rounds. The most recent funding activity was a Series D round of $2.54 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Verax Biomedical
Verax Biomedical has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include BioVentures MedTech Funds, Teknoinvest and KB Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in emerging and growth-stage MedTech companies is facilitated.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused VC firm investing in early stage startups in the US
|
Locked | Locked | Locked |
Investor details for Verax Biomedical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Verax Biomedical
Investment portfolio details for Verax Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Verax Biomedical
Detailed financials for Verax Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Verax Biomedical Comparisons
Peer comparison for Verax Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Verax Biomedical
Verax Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, Avails Medical, Resistell, NOWDiagnostics and HandyLab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| Locked | Locked | Locked |
Antibiotic susceptibility testing is provided via bacterial movement detection.
|
|
| Locked | Locked | Locked |
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays and automation platforms are developed.
|
|
| Locked | Locked | Locked |
Instruments and assays for molecular pathogen detection are developed.
|
Detailed competitors of Verax Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verax Biomedical
Complete news archive for Verax Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verax Biomedical
Verax Biomedical was founded in 1999 and raised its 1st funding round 4 years after it was founded.
Verax Biomedical is headquartered in Marlborough, United States. It is registered at Marlborough, Massachusetts, United States.
Verax Biomedical is a funded company, having raised a total of $72.3M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Verax Biomedical is 23.
Annual revenue of Verax Biomedical is $498.01K as on Dec 31, 2023.
Verax Biomedical was founded in 1999 and is based in Marlborough, United States, within the biomedical diagnostics sector. Pan-genera detection tests are developed by the company to identify bacterial contaminants in cells and tissues for transfusion and transplantation, utilizing conserved antigens from gram-positive and gram-negative bacteria. Operations include the Platelet PGD test, Red Blood PGD test, Cell Therapy PGD test, and 7-day platelet dating, as available in February 2016.
Verax Biomedical's top competitors include Avails Medical, OpGen and NOWDiagnostics.
Verax Biomedical offers Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test.
Verax Biomedical has 6 investors. Key investors include BioVentures MedTech Funds, Teknoinvest, KB Partners, Clark Enterprises, and Sightline Partners.